Boehringer Ingelheim announced that Gilotrif (afatinib) tablets will be commercially available in the U.S. beginning the week of September 2.
The FDA approved Gilotrif on July 12, 2013 as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitutions, as detected by an FDA-approved test.
Gilotrif is an oral, once-daily kinase inhibitor that targets and irreversibly inhibits EGFR (ErbB1), HER2 (ErbB2) and ErbB4 receptors. Along with Gilotrif, the FDA approved to market Qiagen N.V.’s theracreen EGFR RQG PCR Kit as a companion diagnostic.
Gilotrif will be available in 20mg, 30mg, and 40mg strength tablets in 30-count bottles.
For more information, call (800) 542-6257 or visit Boehringer-Ingelheim.com.